{
  "docId": "019de075-e64c-773b-a5bd-08e51f7033a7",
  "docSlug": "8122e3ca3ef658190e4851ff70e19f61",
  "documentTitle": "Arbutus Biopharma | Investor Presentation Deck | 25 slides",
  "authorId": "arbutus-biopharma",
  "authorName": "Arbutus Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 23,
  "pageCount": 25,
  "prevPage": 22,
  "nextPage": 24,
  "slideType": "solution",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a three-column layout to explain the scientific basis and product advantages.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-e64c-773b-a5bd-08e51f7033a7/23",
  "deckHref": "/decks/019de075-e64c-773b-a5bd-08e51f7033a7",
  "deckJsonHref": "/decks/019de075-e64c-773b-a5bd-08e51f7033a7.json",
  "deckAnchorHref": "/decks/019de075-e64c-773b-a5bd-08e51f7033a7#slide-23",
  "components": [
    {
      "bbox": {
        "h": 0.06,
        "w": 0.86,
        "x": 0.07,
        "y": 0.82
      },
      "kind": "callout",
      "text": "Currently in a Phase 1a/1b clinical trial",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c218aa7e-844a-4d26-9c9a-a1b660824b39",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.28,
        "x": 0.65,
        "y": 0.23
      },
      "kind": "list",
      "text": "AB-101: Blocks PD-L1/PD-1 interaction; Activates HBV-specific immune responses; Novel MOA identified; Demonstrates robust checkpoint mediated in vivo effect; Improves HBV-specific T- and B-cell responses.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "476c3f1f-0418-45f4-bfc8-ba52224026a9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.28,
        "x": 0.36,
        "y": 0.23
      },
      "kind": "list",
      "text": "Small-Molecule Inhibitor Approach: Allows controlled checkpoint blockade; Enables oral dosing; Designed to reduce systemic safety issues seen with Abs.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c7e6e00a-93d0-4f12-8851-548e6cbb902d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.28,
        "x": 0.07,
        "y": 0.23
      },
      "kind": "list",
      "text": "Rationale: HBV immune tolerance is a critical driver of cHBV infection; PD-1:PD-L1 checkpoint axis plays a key role; PD-L1 expression upregulated; PD-1 upregulated; Inhibition associated with HBsAg loss.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f4d90d38-10b8-4ac0-8891-666455facd40",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.25,
        "x": 0.14,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "PD-1: Programmed death ligand protein | Abs: Antibodies",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "96314031-741a-4a69-a82a-e13985cb3f97",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.86,
        "x": 0.07,
        "y": 0.06
      },
      "kind": "title",
      "text": "AB-101: Oral PD-L1 Inhibitor for HBV Immune Reactivation",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1e5f2f6d-4de9-4e67-91b2-515e8568e101",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Problem-Agitate-Solve (PAS)",
      "slug": "problem-agitate-solve-pas",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "f0ecf675-62d9-4c4f-ae2b-cfad5c3c3343",
      "evidence": "The slide presents a problem (HBV immune tolerance), agitates it (by highlighting the role of PD-1:PD-L1 checkpoint axis), and offers a solution (AB-101, a small-molecule oral PD-L1 inhibitor).",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}